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Effect of Rehabilitation on Sleep Quality
After Ablation for Atrial Fibrillation
Data From a Randomized Trial
Signe Stelling Risom, PhD, RN; Pernille Fevejle Cromhout, MSc, RN; Dorthe Overgaard, PhD, RN;
Jesper Hastrup Svendsen, MD, DMSc; Selina Kikkenborg Berg, PhD, MScN, RN
Background: Low sleep quality is common in patients with atrial fibrillation (AF). Positive effects of cardiac
rehabilitation on patients treated for AF with ablation have been found, but whether cardiac rehabilitation
affects sleep quality is unknown. The objectives of this study were to investigate (1) differences in sleep quality
between cardiac rehabilitation and usual care groups and (2) whether other factors could affect sleep quality.
Methods: From the randomized CopenHeartRFA trial, 210 patients treated for AF with ablation were included. A
rehabilitation program consisting of physical exercise and psychoeducational consultations was tested. Sleep
quality was measured with the Pittsburg Sleep Quality Index (PSQI) questionnaire before intervention and at
the end of intervention. Anxiety, depression, and European Heart Rhythm Association scores were assessed.
Results: No difference between groups in sleep quality was found (PSQI global mean [SD] score, 6.60 [3.61]
points for the cardiac rehabilitation group [n = 83] and 6.08 [3.60] points for the usual care group [n = 90];
P = .34), although improvements in sleep quality were noted in both groups. Sleep latency, duration, and efficiency were
significant by type of AF at 1 month. Anxiety, depression, and higher European Heart Rhythm Association scores at 4
months were associated with a higher PSQI global mean score at the end of intervention. Conclusion: The rehabilitation
program showed no effect on sleep quality. A large proportion of patients reported poor sleep quality, and patients
reporting anxiety, depression, or AF symptoms described worse sleep quality compared with patients who did not
experience anxiety, depression, or AF symptoms. More research in the field is warranted.
KEY WORDS: atrial fibrillation, cardiac rehabilitation, cardiovascular diseases, sleep
Sleep is a fundamental behavior that has been shownto be associated with morbidity and recovery. Dis-
turbed sleep is reported by up to 70% of patients with
heart disease.1 Research findings have contributed to
an increasing awareness of sleep and sleep disorders.
Disturbance and lack of sleep are associated with a
number of dysfunctions such as mood disturbance, ex-
cessive exhaustion, decreased alertness, and reaction
time and have a negative effect on daytime functioning
and quality of life.2 Sleep disorders increase the risk of
morbidity and mortality and can contribute to the
development of conditions such as hypertension and
heart failure.3,4
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Atrial fibrillation (AF) affects approximately 2%
of the population in the Western world.5Y7 The pre-
valence of AF is growing mainly because of the in-
creasing age of our population and because AF can
be observed as a complication from other heart diseases
where improved treatments have led to an increased
number of patients living with heart disease.6,8,9 Symp-
toms of AF include palpitations, dyspnea, fatigue,
dizziness, and syncope,10,11 and AF is observed as
having a negative effect on sleep quality.12
A study by Szymanski and colleges12 showed that low
sleep quality is common in patients with AF and affects
nearly 50%. Patients with AF have shorter sleep duration
and lower self-reported sleep quality than patients in
sinus rhythm.12 Sleep quality may be especially critical
to patients with AF due to shortness of breath and the
disruptive experience of heart palpitations.13
The cardiac rehabilitation trial, CopenHeart, in-
cluded exercise training and psychoeducational con-
sultations and demonstrated a positive primary
outcome, physical capacity in patients treated with
catheter ablation for AF (cardiac rehabilitation group
vs usual care group, 24.3 vs 21 mL/kg per min; P =
.003).14 Studies have found that lifestyle rehabilita-
tion related to sleep has positive outcomes on heart
patients. The interventions have included diet, exer-
cise, weight reduction, and lifestyle modification.15
However, to our knowledge, no investigators have
investigated the effect of cardiac rehabilitation on sleep
quality in patients treated with ablation for AF.
Therefore, the objectives of this study were to
investigate (1) differences in sleep quality between
the cardiac rehabilitation and usual care groups using
data from the CopenHeart trial and (2) to explore
variables that possibly could affect sleep quality.
Methods
Design
This study is an explorative study and reports results
on sleep quality from the CopenHeart trial.14,16 In the
CopenHeart trial, a comprehensive rehabilitation pro-
gram was designed and tested for patients treated for AF
with catheter ablation in 2 university hospitals in Denmark.
The intervention is described in detail elsewhere.16
Trial Patients and Intervention
In total, 210 consecutive patients treated with radio-
frequency catheter ablation for AF were included in
the CopenHeart trial. Patients 18 years or older, Danish
speaking, and providing oral and written informed
consent were eligible for participation. The following
patients were excluded: (1) those unable to under-
stand trial instructions; (2) pregnant or breastfeeding
women; (3) those with a reduced ability to follow the
planned program due to other physical illness; (4) those
who, before ablation, had been engaged in intense phys-
ical exercise or sports at a competitive level several times
a week; or (5) those who were enrolled in a clinical trial
that prohibited participation in additional trials.
Patients were centrally randomized 1:1 to compre-
hensive cardiac rehabilitation plus usual care (cardiac
rehabilitation group vs usual care group). Outcome assess-
ment, data management, analyses, and conclusions were
performed by a blinded statistician and research staff.
The intervention consisted of usual care, which
included 1 consultation at 3 to 4 months with a car-
diologist at the treating hospital and, in addition, a
physical exercise program and psychoeducational
consultations. The physical exercise program was
designed to increase physical capacity measured by
VO2 peak. The training program consisted of gradu-
ated cardiovascular training based on intensity pre-
scription using the Borg scale17 and strength exercises
altered stepwise during training sessions. The pro-
gram included 3 sessions per week for 12 weeks.
The aim of the psychoeducational consultations
was to provide emotional support and improve coping
skills and illness appraisal to enable the patients to
respond appropriately to physical and psychological
symptoms. The psychoeducational consultations were
inspired by the 3 dimensions described in Parse’s18
Human Becoming Practice Methodologies. The pa-
tients were offered four 1-hour consultations over the
first 6 months after enrollment. There were no specific
interventions carried out that focused on sleep quality,
but sleep could have been discussed in the psycho-
educational consultations if wanted by the patient.
Ethics
The trial was approved by the local ethics committee
(number H-1-2011-135) and the Danish Data Protec-
tion Agency (registration number 2007-58-0015). It
was registered at ClinicalTrials.gov (NCT01523145)
and complied with the Declaration of Helsinki.
Outcome Measure
The outcome measure for this study is sleep quality.
The patients in the CopenHeart trial answered a
questionnaire exploring their sleep quality at month 1
(before intervention) and month 6 (end of interven-
tion). To explore the effect of other outcomes on sleep
quality, anxiety, depression, and the severity of AF
symptoms measured by the European Heart Rhythm
Association (EHRA) scores were examined at 4 months
(end of the physical exercise program).
Pittsburgh Sleep Quality Index
Sleep quality was measured by the Pittsburg Sleep
Quality Index (PSQI) questionnaire.19 Psychometric
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evaluation of the PSQI is limited, but studies indicate
that it has overall high internal homogeneity, internal
consistency, and test-retest reliability20 and its validity
has been confirmed in various patient groups.2,21Y24 A
Cronbach’s ! of .83 was demonstrated for internal
consistency reliability, and validity was demonstrated
as the PSQI distinguishes patients with a sleeping
disorder from patients without one.25
The self-rated questionnaire consists of 14 ques-
tions concerning factors that might influence sleep
quality. Five additional questions are answered by
the bed partner or roommate. From the 19 ques-
tions, 7 component scores are grouped, all weighted
equally on a 0-to-3 scale. The components include
subjective sleep quality, sleep latency, sleep dura-
tion, habitual sleep efficiency, sleep disturbances,
use of sleeping medications, and daytime dysfunc-
tion due to sleepiness. From the 7 component scores,
a global score can be calculated. The PSQI global
score ranges from 0 to 21. High scores indicate poor
sleep quality. Patients scoring higher than 5 on PSQI
global are characterized as poor sleepers.19 Patients
were asked to fill out the questionnaire from usual
sleep habits over the previous 30 days.
Hospital Anxiety and Depression Scale
Patients with symptoms of anxiety or depression
were identified by the Hospital Anxiety and Depres-
sion Scale (HADS) questionnaire. The HADS consist
of 14 items on 2 subscales: an anxiety scale (HADS-A)
and a depression scale (HADS-D), with each scale
including 7 items. Each item is rated from 0 to 3
points. Seven is considered a cutoff score for each
subscale, a score from 0 to 7 is considered normal,
and scores of 8 or higher indicate the presence of a
clinical mood disorder.26,27 The HADS is exten-
sively validated and recommended for use in cardiac
patients.28 It is a generic instrument to identify
patients with symptoms of anxiety and/or depres-
sion.26 Internal consistency is considered high, with
a Cronbach’s ! of .83 for HADS-A and .82 for
HADS-D.27
Statistical Analysis
Differences between groups for baseline results for
PSQI at 1 month were tested using independent sam-
ples t test for binary variables. Levene test was used to
verify the assumption of equal variances. Analysis of
variance was used to detect whether there were age
differences between groups. The difference between
the intervention and usual care groups at 6 months
was tested using independent samples t test.
To examine the effect of intervention group, anx-
iety, depression, type of AF, and the severity of AF
symptoms (EHRA scores) on sleep quality, a linear
regression model was used including variables mea-
sured at month 4 that were believed to possibly affect
sleep quality. The model was adjusted for intervention
group, age, sex, smoking, living with partner, educa-
tional level, and PSQI score at 1 month. An indepen-
dent t test was undertaken to compare means for EHRA
score, HADS-A and HADS-D, type of AF, and inter-
vention group. All analyses were undertaken using
SPSS version 22 (IBM Corp, Armonk, New York), and
statistical significance was attained at P e .05.
Results
At month 1, 194 (of 210 randomized patients) (92%)
answered the PSQI questionnaire (98 from the cardiac
rehabilitation group and 96 from the usual care group),
and 173 patients (82%) answered the PSQI question-
naire at month 6 (83 from the cardiac rehabilitation
group and 90 from the usual care group).
Baseline characteristics showed that the cardiac reha-
bilitation and usual care groups were well matched at
baseline (Table 1). Mean age was 59 years, and approx-
imately two-thirds were male (cardiac rehabilitation
group, n = 74; usual care group, n = 77). Greater than
50% of the patients had more than 3 years of college
education (cardiac rehabilitation group, n = 58; usual
care group, n = 51). Patients in the cardiac rehabilita-
tion group had a mean body mass index (BMI) of 27,
and patients in the usual care group had a mean BMI of
28. Approximately 50% of the patients were taking "-
blockers (cardiac rehabilitation group, n = 55; usual
care group, n = 56).
At month 1 (Table 2), the overall PSQI global
mean scores for patients with paroxysmal AF showed
significantly longer sleep duration (P = .02) and worse
sleep efficiency (P = .05) than patients with persistent
AF. By contrast, patients with persistent AF had
worse sleep latency (P G .01). Patients with a BMI of
24.9 or lower had better sleep latency than patients
with a BMI of 25 and higher (P = .02), whereas
patients with a BMI of 25 and higher experienced
more sleep disturbances (P = .01).
The global mean (SD) score for PSQI at month 6
in the cardiac rehabilitation group (n = 83) was 6.60
(3.61), and in the usual care group, it was (n = 90) 6.08
(3.60; P = .34). At 1 month, 85% of the patients re-
ported poor sleep quality (87% in the cardiac reha-
bilitation group and 82% in the usual care group). At
6 months, 55% of the patients reported poor sleep
quality (58% in the cardiac rehabilitation group and
52% in the usual care group).
Regression analysis (Table 3) demonstrated that higher
EHRA scores at 4 months were associated with a higher
PSQI global mean score at 6 months (PSQI global mean
[SD] score, 5.93 [3.05] for EHRA 1Y2 vs 7.59 [4.26] for
EHRA 3Y4). The same was found for HADS-A and
Effect of Rehabilitation on Sleep Quality 263
HADS-D where an association between higher scores
were found with higher scores of PSQI global (PSQI
global mean [SD] score, 5.73 [3.13] for HADS-A Q 8 vs
8.46 [4.81] for HADS-D Q 8; P = .02). No statistically
significant difference was seen for type of AF or inter-
vention group versus usual care group.
Discussion
Sleep quality is low in most patients with heart disease.
For example, in patients with heart failure, 63% report
poor sleep quality that is associated with reduced
cardiac event-free survival.29 In AF specifically, sleep
quality is poor in 50% to 55% of patients.12,30,31 In
this exploratory study, we examined sleep quality
among AF patients being treated with ablation and
who then participated in a randomized rehabilitation
trial. There was no difference in sleep quality between
the cardiac rehabilitation and usual care groups.
However, 85% of all patients reported poor sleep
quality at 1 month, and 55% reported poor sleep
quality at 6 months. In comparison, the prevalence
of poor sleep quality was found to be 38% in the
general population in a large cross-sectional study in
2016.32 The lack of difference in sleep quality found
between the cardiac rehabilitation and usual care
groups was also seen in a study including patients
with an ICD.30 We also found that more symptomatic
patients experienced poorer sleep quality and patients
with high scores for anxiety and depression experi-
enced poorer sleep quality compared with patients
with low scores regardless of type of AF.
It is notable that a high number of patients in this
study reported low sleep quality even 6 months after
ablation when most patients should be in sinus
rhythm. Sleep quality has been reported to be low in
other cardiac patient groups participating in cardiac
rehabilitation for myocardial infarction, coronary
artery bypass surgery, or cardiac catheterization.33
Depression is associated with poor sleep quality.34
According to the International Classification of
Disease, 10th Revision, sleep disturbance is a symp-
tom of depression35 and sleep disorder can be a
predictor for depressive relapse, as well as sleep
disturbances can lead to depression.36 This is in line
with the findings in this study where it was demon-
strated that patients with high scores for depression
had poor sleep quality.
We found that worse AF symptoms were associ-
ated with poor sleep quality. When comparing the
EHRA and PSQI scores from this study with the re-
sults that Szymanski and colleagues12 reported, the
same trend is observed in that patients with more AF
symptoms experienced worse sleep quality. The rela-
tion between AF symptoms and sleep quality is mul-
tifactorial. Atrial fibrillation is associated with an
increase in sympathetic activity that can produce
symptoms and result in poor sleep quality.37 More-
over, symptoms of AF, depression, anxiety, and poor
sleep quality are linked and mutually reinforcing.
These findings suggest that future interventions
targeting sleep quality in patients with AF should
include elements to decrease AF symptoms, depres-
sion, and anxiety. The intervention tested in the
CopenHeart trial aimed at providing emotional sup-
port and improving coping skills and illness appraisal
to enable patients to respond appropriately to physical
and psychological symptoms. Therefore, we had
hypothesized that the intervention could have an
influence on sleep quality, as well as the primary and
secondary outcomes. Our results suggest that, in addition
to addressing negative emotions, it is important to
directly address poor sleep quality as well.
In recent years, obstructive sleep apnea has been
found to be a strong predictor of AF with up to 40%
to 50% of AF patients experiencing obstructive sleep
apnea.38,39 Sleep apnea is associated with antidys-
rhythmic drug failures after cardioversion or catheter
ablation, AF recurrence, and an increase of greater
TABLE 1 Patients’ Baseline Demographics
Intervention Control
n (%) n (%)
Age, mean (SD), y 60 (9.7) 59 (12.3)
Sex (male) 74 (70.5) 77 (73.3)
Living with partner 82 (78.1) 85 (81)
Educational level
G3 y of college education 58 (60.9) 51 (53.6)
Type of AF
Paroxysmal 76 (72.4) 76 (72.4)
Persistent 29 (27.6) 29 (27.6)
Symptoms of AF
Palpitations 68 (64.8) 53 (50.5)
Angina 19 (18.1) 16 (15.2)
Dyspnea 62 (59) 64 (61)
Dizziness 71 (68) 77 (73)
Fatigue 60 (57) 48 (46)
Syncope 2 (1.9) 3 (2.9)
BMI, mean (SD), kg/m2 27 (4.4) 28 (5.6)
Smoking, mean (SD)
Current smoking 2 (1.9) 3 (2.9)
Medications
"-Blocker 55 (52.4) 56 (53.3)
Other antidysrhythmics 7 (6.9) 3 (2.9)
Diuretics 5 (4.8) 3 (2.9)
Psychotropic medication 3 (2.9) 6 (5.7)
Sleep medication or morphine 1 (1) 2 (1.9)
EHRA score
1Y2 60 (57.1) 60 (57.1)
3Y4 44 (41.9) 45 (42.9)
Treatment
Previous ablation 41 (39.1) 49 (46.7)
Previous cardioversions 49 (46.7) 54 (51.4)
Abbreviations: AF, atrial fibrillation; BMI, body mass index; EHRA,
European Heart Rhythm Association.
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than 3-fold in ischemic stroke.40Y43 A connection be-
tween obstructive sleep apnea and AF is associated
with significant atrial remodeling that is character-
ized by atrial enlargement, reduction in voltage, site-
specific and widespread conduction abnormalities,
and longer sinus node recovery.44 Rehabilitation pro-
grams that included diet and lifestyle management
interventions for adults with obstructive sleep apnea
have shown that lifestyle interventions are effective in
reducing weight and therefore also improve obstruc-
tive sleep apnea parameters.15 Screening for obstruc-
tive sleep apnea is not included in the PSQI; thus, it is
not known how many of the patients in our study also
experienced obstructive sleep apnea, but patients with
a BMI of 25 and higher experienced more sleep dis-
turbances in this study.
Limitations
These analyzes were explorative, meaning that the sam-
ple size calculation was done to examine an effect of the
primary (physical capacity measured by VO2 peak) and
secondary (quality of life, measured on Short Form-36,
Mental Component Scale) outcomes for the CopenHeart
trial and not for the sleep analyses.16 Therefore, the
results should be considered as hypothesis generating
for future trials. The PSQI has not been validated in an
AF population, which is a limitation.
Conclusion and Perspectives
The cardiac rehabilitation program in this study
consisted of physical exercise and psychoeducational
TABLE 3 Effect of Intervention on Quality of
Sleep at 6 Months and Variables That Possibly
Could Affect Sleep Quality
PSQI Global Score
at 6 mo, Mean (SD)a P
EHRA score
1Y2 (n = 111) 5.93 (3.05) .01
3Y4 (n = 29) 7.59 (4.26)
HADSb
HADS-A G 8 (n = 129) 5.73 (3.13) G.01
HADS-A Q 8 (n = 28) 8.75 (4.41)
HADS-D G 8 (n = 144) 6.07 (3.39) .02
HADS-D Q 8 (n = 13) 8.46 (4.81)
Type of AF
Paroxysmal (n = 119) 6.41 (3.77) .50
Persistent (n = 43) 5.86 (2.79)
Intervention group
Intervention group (n = 77) 6.57 (3.56) .34
Control group (n = 85) 5.99 (3.52)
Abbreviations: AF, atrial fibrillation; EHRA, European Heart Rhythm
Association; HADS, Hospital Anxiety and Depression Scale; PSQI,
Pittsburgh Sleep Quality Index.
aAdjusted for baseline characteristics, month 1 PSQI global score, and
intervention group.
bMeasured at month 4.
T
A
B
L
E
2
B
a
se
li
n
e
C
ro
ss
-s
e
ct
io
n
o
f
S
le
e
p
Q
u
a
li
ty
o
n
A
ll
D
o
m
a
in
s
a
t
P
it
ts
b
u
rg
h
S
le
e
p
Q
u
a
li
ty
In
d
e
x
M
e
a
su
re
d
a
t
1
M
o
n
th
,
C
o
n
ti
n
u
e
d
S
u
b
je
ct
iv
e
S
le
e
p
Q
u
a
li
ty
S
le
e
p
La
te
n
cy
S
le
e
p
D
u
ra
ti
o
n
H
a
b
it
u
a
l
S
le
e
p
E
ff
ic
ie
n
cy
S
le
e
p
D
is
tu
rb
a
n
ce
s
S
le
e
p
M
e
d
ic
a
ti
o
n
s
D
a
y
ti
m
e
D
y
sf
u
n
ct
io
n
O
v
e
ra
ll
P
S
Q
I
S
co
re
(G
lo
b
a
l)
M
e
a
n
(S
D
)
P
M
e
a
n
(S
D
)
P
M
e
a
n
(S
D
)
P
m
ea
n
(T
SD
)
P
M
e
a
n
(S
D
)
P
M
e
a
n
(S
D
)
P
M
e
a
n
(S
D
)
P
M
e
a
n
(S
D
)
P
Fa
ti
g
u
e
Y
e
s
1
.0
2
(0
.8
2
)
.3
1
2
.9
4
(0
.2
3
)
.0
9
0
.8
3
(0
.6
6
)
.6
3
0
.5
9
(0
.8
5
)
.3
1
1
.4
1
(0
.5
8
)
.6
9
0
.2
8
(0
.7
0
)
.4
3
0
.8
9
(0
.6
4
)
.4
3
7
.7
9
(2
.6
2
)
.3
5
N
o
1
.1
3
(0
.7
1
)
2
.8
6
(0
.4
7
)
0
.8
8
(0
.6
7
)
0
.7
4
(1
.0
1
)
1
.4
4
(0
.5
4
)
0
.3
7
(0
.8
7
)
0
.8
2
(0
.6
2
)
8
.1
3
(2
.4
8
)
S
yn
co
p
e
Y
e
s
1
.5
0
(1
)
.2
7
2
.5
0
(0
.5
8
)
.0
4
1
(0
.8
2
)
.6
7
1
.5
0
(1
.2
9
)
.0
8
1
.7
5
(0
.5
0
)
.2
4
0
.5
0
(1
.0
0
)
.6
6
1
.2
5
(0
.5
0
)
.2
0
1
0
.0
(2
.5
8
)
.1
1
N
o
1
.0
7
(0
.7
6
)
2
.9
1
(0
.3
7
)
0
.8
5
(0
.6
7
)
0
.6
5
(0
.9
3
)
1
.4
2
(0
.5
6
0
.3
2
(0
.8
)
0
.8
4
(0
.6
3
)
7
.9
3
(2
.5
3
)
M
e
d
ic
a
ti
o
n
s,
"
-b
lo
ck
e
rs
Y
e
s
1
.1
0
(0
.7
9
)
.7
8
2
.8
9
(0
.3
9
)
.8
9
0
.8
3
(0
.6
)
.5
9
0
.6
6
(0
.9
3
)
.8
3
1
.4
7
(0
.5
7
)
.3
1
0
.2
8
(0
.7
5
)
.4
1
0
.8
6
(0
.6
1
)
.7
5
7
.9
3
(2
.3
2
)
.8
1
N
o
1
.0
7
(0
.7
4
)
2
.9
0
(0
.3
7
)
0
.8
9
(0
.7
4
)
0
.6
9
(0
.9
6
)
1
.3
8
(0
.5
3
)
0
.3
8
(0
.8
6
)
0
.8
4
(0
.6
5
)
8
.0
2
(2
.7
8
)
E
H
R
A
sc
o
re
1
Y2
1
.0
4
(0
.7
8
)
.3
1
2
.9
0
(0
.3
5
)
.7
9
0
.8
1
(0
.6
6
)
.2
5
0
.6
4
(0
.9
6
)
.5
6
1
.4
0
(0
.5
3
)
.4
3
0
.3
0
(0
.7
5
)
.6
9
0
.8
1
(0
.6
3
)
.2
5
7
.8
0
(2
.6
5
)
.2
5
3
Y4
1
.1
5
(0
.7
5
)
2
.8
9
(0
.4
2
)
0
.9
3
(0
.6
7
)
0
.7
3
(0
.9
3
)
1
.4
6
(0
.5
9
)
0
.3
5
(0
.8
7
)
0
.9
1
(0
.6
4
)
8
.2
3
(2
.3
4
)
A
b
b
re
vi
a
ti
o
n
s:
A
F,
a
tr
ia
l
fi
b
ri
lla
ti
o
n
;
B
M
I,
b
o
d
y
m
a
ss
in
d
e
x;
E
H
R
A
,
E
u
ro
p
e
a
n
H
e
a
rt
R
h
yt
h
m
A
ss
o
ci
a
ti
o
n
;
P
S
Q
I,
P
it
ts
b
u
rg
h
S
le
e
p
Q
u
a
lit
y
In
d
e
x.
a
C
o
lle
g
e
e
d
u
ca
ti
o
n
.
266 Journal of Cardiovascular Nursing x May/June 2018
consultations. The program showed no effect on sleep
quality. A large proportion of patients continued to
report poor sleep quality regardless of group assign-
ment. More symptomatic patients and patients
experiencing higher levels of depressive or anxiety
symptoms reported poor sleep quality. That is a
concern because sleep quality is vital for a person’s
physical and mental health, and therefore it could be
argued that screening for sleep quality should be
prioritized by health professionals caring for patients
with AF. Screening for depression or anxiety may
benefit AF patients with poor sleep quality. Treatment
for depression or anxiety can be offered with the aim of
also improving the patients’ sleep quality. Patients with
AF should be examined for sleep disorders and treated
if needed. Intervention trials focusing on sleep quality
in patients with AF or treated for AF are warranted to
guide health professionals in supporting the patients to
better sleep quality. Inspiration can be found in
intervention trials that include patients with other
heart conditions.45 Trials of nonpharmacological in-
terventions designed to improve sleep quality among
patients with AF or treated for AF and interventions
targeting both simple identification of sleep disorders
and therapy directed against diseases such as sleep
apnea are needed.
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